Tareq Abadl: Extravascular Hemolysis The High-Yield Guide
Tareq Abadl, Medical Lab Specialist, shared a post on LinkedIn:
“Extravascular Hemolysis
Where are the RBCs destroyed?
In extravascular hemolysis, RBCs are removed from circulation by macrophages, mainly in the spleen and liver.
What happens in the Lab?
- High Indirect Bilirubin
- Hemoglobin is broken down within macrophages, increasing bilirubin production.
- High Reticulocytes
- The bone marrow responds to increased RBC destruction by increasing RBC production.
- High LDH
- LDH may be elevated as a marker of hemolysis, but it is not specific for extravascular hemolysis.
- Low Haptoglobin
- Haptoglobin can decrease in hemolysis, but this finding occurs in both intravascular and extravascular hemolysis and should not be used alone to distinguish them.
Peripheral blood smear
Spherocytes may be seen, particularly in:
- Hereditary spherocytosis
- Warm autoimmune hemolytic anemia
Hemoglobinuria or Hemosiderinuria
These findings are more characteristic of intravascular hemolysis and are generally absent in typical extravascular hemolysis.
Common Examples
- Warm autoimmune hemolytic anemia
- Hereditary spherocytosis
- Hypersplenism
- Lab memory tip
Extravascular occurs in the spleen and liver
RBCs are broken down by macrophages, leading to heme breakdown and increased indirect bilirubin.
Remember:
Not every hemolysis marker tells you where the RBC was destroyed.
The mechanism plus peripheral smear plus urine findings should be interpreted together.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver